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AbstrAct
Fibroblast growth factor-8b (FGF8b) affects the epithelial/stromal compartments 
of steroid hormone-regulated tumors by exerting an autocrine activity on cancer cells 
and a paracrine pro-angiogenic function, thus contributing to tumor progression. The 
FGF8b/FGF receptor (FGFR) system may therefore represent a target for the treatment 
of steroid hormone-regulated tumors. The soluble pattern recognition receptor long 
pentraxin-3 (PTX3) binds various FGFs, including FGF2 and FGF8b, thus inhibiting the 
angiogenic and tumorigenic activity of androgen-regulated tumor cells. Nevertheless, 
the complex/proteinaceous structure of PTX3 hampers its pharmacological 
exploitation. In this context, the acetylated pentapeptide Ac-ARPCA-NH2 (ARPCA), 
corresponding to the N-terminal amino acid sequence PTX3(100-104), was identified 
as a minimal FGF2-binding peptide able to antagonize the biological activity of 
FGF2. Here, we demonstrate that ARPCA binds FGF8b and inhibits its capacity to 
form FGFR1-mediated ternary complexes with heparan sulphate proteoglycans. As 
a FGF8b antagonist, ARPCA inhibits FGFR1 activation and signalling in endothelial 
cells, hampering the angiogenic activity exerted in vitro and in vivo by FGF8b. Also, 
ARPCA suppresses the angiogenic and tumorigenic potential of prototypic androgen/
FGF8b-dependent Shionogi 115 mammary carcinoma cells and of androgen/FGF8b/
FGF2-dependent TRAMP-C2 prostate cancer cells. In conclusion, ARPCA represents 
a novel FGF8b antagonist with translational implications for the therapy of steroid 
hormone-regulated tumors.
INtrODUctION
Fibroblast growth factor-8 (FGF8), originally 
cloned from an androgen-dependent mouse mammary 
carcinoma cell line, belongs to the angiogenic FGF family 
[1, 2]. Like other members of the FGF family, FGF8 
mediates its cellular responses by binding and activating 
tyrosine kinase FGF receptors (FGFRs) [3]. Experimental 
and clinical evidences point to an autocrine/paracrine 
role of FGF8 in the growth of epithelial/stromal cells 
in steroid hormone-regulated tumors [4, 5], the FGF8 
gene containing a functional androgen-response element 
responsible for its transcriptional activation by steroid-
receptor signalling [6]. Alternatively spliced isoforms 
of the human FGF8 gene allow the transcription of four 
different isoforms designated FGF8a, FGF8b, FGF8e, 
and FGF8f [7]. Among them, FGF8b is endowed with 
the strongest tumorigenic and angiogenic potential [4, 
8]. Indeed, several studies demonstrate that FGF8b 
triggers angiogenesis, tumor growth and invasion in 
prostate cancer [5, 9]. Accordingly, FGF8b transgenic 
expression targeted to the prostate epithelium causes 
prostatic intraepithelial neoplasia (PIN) [10] whereas 
its downregulation inhibits the tumorigenic potential of 
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prostate cancer cells [11]. Also, FGF8b was found to be 
highly expressed in breast and ovarian cancers [4, 8]. 
Thus FGF8b represents a possible druggable target for 
multidrug or multimodality treatment of steroid hormone-
regulated tumors [4, 6].
The soluble pattern recognition receptor long 
pentraxin-3 (PTX3) is a member of the pentraxin family 
produced locally in response to inflammatory signals [12]. 
Previous observations had shown that PTX3 binds various 
FGFs via its N-terminal extension, including FGF2, FGF6, 
FGF8b, FGF10 and FGF17 [13-16], and inhibits FGF2-
dependent angiogenic responses [16, 17]. Accordingly, 
transgenic PTX3 overexpression efficaciously impairs the 
activation and signaling of the FGF/FGFR system in FGF-
driven tumor cell lines, thus affecting tumor growth and 
metastasis [15, 16, 18]. In particular, PTX3 inhibits the 
angiogenic and tumorigenic activity of androgen-regulated 
tumor cells in which testosterone activates a FGF8b-
dependent autocrine/paracrine loop of stimulation [15]. 
PTX3 is a 340 kDa protein composed of eight 381 
amino acid protomers [19]. The complex proteinaceous 
structure of PTX3 hampers its pharmacological 
exploitation. In this context, the 480 Da acetylated 
pentapeptide Ac-ARPCA-NH2 (in single letter code, 
hereafter referred to as ARPCA), corresponding to the 
N-terminal amino acid sequence PTX3(100-104), was 
identified as a minimal anti-angiogenic FGF2-binding 
peptide able to interfere with the biological activity of 
FGF2 [20]. Thus, ARPCA may represent an interesting 
FGF-trap molecule for the treatment of FGF-dependent 
tumors.
Here, we demonstrate the capacity of ARPCA 
to bind FGF8b, thus inhibiting its angiogenic activity 
in vitro and in vivo. Accordingly, ARPCA suppresses 
the angiogenic and tumorigenic potential of prototypic 
androgen/FGF8b-dependent Shionogi 115 (S115) 
mammary carcinoma cells [21] and of androgen/FGF8b/
FGF2-dependent TRAMP-C2 prostate cancer cells [22]. 
Thus, ARPCA represents a novel FGF8b antagonist with 
possible implications for the therapy of steroid hormone-
regulated tumors.
rEsULts
ArPcA binds and antagonizes FGF8b
The capacity of ARPCA to bind FGF8b was assessed 
by surface plasmonic resonance (SPR) spectroscopy 
[20]. To this purpose, increasing concentrations of the 
peptide were injected over a BIAcore sensor chip coated 
with the immobilized growth factor. As shown in Figure 
1A, ARPCA binds to immobilized FGF8b in a dose-
dependent manner with a Kd value equal to 278 ± 120 µM. 
On this basis, to assess the role of each ARPCA amino 
acid residue for FGF8b interaction, a series of synthetic 
peptides harboring different amino acid substitutions were 
assessed for their FGF8b binding activity by SPR analysis 
on the FGF8b-coated sensor chip. 
As shown in Figure 1B, the partially scrambled 
Ac-APCRA-NH2 peptide did not show any significant 
inhibitory activity in this assay, pointing to the relevance 
of the relative position of RPC residues for the FGF8b 
antagonist capacity of the peptide. The activity was lost 
also when the Pro3 residue was replaced in Ac-ARACA-
NH2 and Ac-ARGCA-NH2 peptides or when the Cys4 
residue was replaced in Ac-ARPSA-NH2, Ac-ARPMA-
NH2, and Ac-ARPVA-NH2 peptides, thus underlying 
the role of the RPC amino acid sequence in ARPCA/
FGF8b interaction. Interestingly, as observed for ARPCA/
FGF2 interaction [20], the FGF8b binding activity was 
dramatically reduced for the non-acetylated H-ARPCA-
NH2 peptide and for the Ac-ARPCG-NH2 and Ac-GRPCG-
NH2 peptides, indicating a role for the N-terminal blocking 
methyl group and for the methyl group of the side-chain of 
Ala1 and Ala5 residues in FGF8b interaction. 
In order to characterize the structural basis of 
ARPCA/FGF8b binding interactions, FGF8b was titrated 
into a solution of ARPCA peptide and a series of 2D 13C-1H 
HSQC NMR experiments were recorded to follow peptide 
resonances. Progressive chemical shift variations were 
observed for Hα signals of Ala1 and Ala5 residues of the 
pentapeptide (Figure 1C), indicating that ARPCA makes 
specific interactions with FGF8b, mainly mediated by the 
two Ala residues. The titration progress was indicative of 
an intermediate to fast exchange phenomenon, pointing 
to a binding in the micromolar range, in good agreement 
with SPR data. Taken together, these results identify 
the ARPCA pentapeptide as a FGF8b binder. On this 
basis, ARPCA was further characterized for its capacity 
to interact with FGF8b and to antagonize its biological 
activity. The Ac-ARPVA-NH2 pentapeptide (hereafter 
named ARPVA) was used as a negative control.
FGFs exert their biological activity by leading 
to the formation of productive ternary complexes with 
signalling FGFRs and cell-surface heparan sulphate 
proteoglycans (HSPGs) [23]. On this basis, to investigate 
its FGF8b antagonist potential, ARPCA was evaluated for 
the capacity to prevent the formation of HSPG/FGF8b/
FGFR1 ternary complexes in a cell-cell adhesion model 
in which FGF8b mediates the adhesion of FGFR1(III)
c-overexpressing HSPG-deficient CHO cells to a HSPG-
bearing CHO cell monolayer [16]. As shown in Figure 
1D, ARPCA, but not ARPVA, exerts a dose-dependent 
inhibitory activity on FGF8b-mediated cell-cell adhesion 
(ID50 ~10 µM), thus indicating the capacity of the 
peptide to interfere with HSPG/FGF8b/FGFR1 complex 
formation.
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ArPcA inhibits the angiogenic activity of FGF8b
FGF8 acts on endothelial cells leading to the 
activation of the angiogenic process in vitro and in vivo 
[21]. In a first set of experiments, the capacity of ARPCA 
to impair the pro-angiogenic activity of FGF8b was 
assessed in vitro on human umbilical vein endothelial cells 
(HUVECs). In keeping with its capacity to prevent the 
formation of signaling HSPG/FGF8b/FGFR complexes, 
ARPCA, but not ARPVA, efficiently impairs FGFR1 
phosphorylation triggered by FGF8b in HUVECs (Figure 
2A). Accordingly, ARPCA inhibits HUVEC proliferation 
in response to FGF8b with an IC50 value equal to ~30 µM 
whereas no significant effect was observed when cells 
were treated with ARPVA at concentrations as high as 300 
µM (Figure 2B). Also, ARPCA specifically prevents the 
pro-angiogenic/sprouting activity exerted by FGF8b on 
HUVEC spheroids embedded in fibrin gel with no effect 
on the angiogenic potential of vascular endothelial growth 
factor-A (VEGF-A), thus supporting the FGF-restricted 
specificity of the inhibitory effect (Figure 2C).
Finally, the capacity of ARPCA to affect FGF8b-
induced neovascularization was investigated in vivo in 
a chick embryo chorioallantoic membrane (CAM) assay 
[24]. In this assay, alginate beads adsorbed with FGF8b 
(4.5 pmoles/plug) induce a potent angiogenic response 
when compared to control beads adsorbed with vehicle 
(Figure 2D). In keeping with the in vitro observations, the 
angiogenic response elicited by FGF8b was significantly 
reduced by the addition of 80 or 140 pmoles of ARPCA to 
the FGF8b implants (P < 0.0001). No inhibitory effect was 
instead exerted by control ARPVA or when ARPCA was 
challenged in the presence of VEGF-A as a pro-angiogenic 
stimulus (Figure 2D).
Figure 1: ArPcA binds and antagonizes FGF8b. A. SPR analysis of ARPCA binding to immobilized FGF8b. b. Increasing 
concentrations of ARPCA and of peptide mutants were tested by SPR analysis for the capacity to bind the FGF8b sensor chip and the 
affinity of interaction (Kd, mean ± SEM) was calculated for each peptide. nb, no binding. A schematic representation of ARPCA peptide 
is shown on the right. c. Overlay of selected region of 2D 1H-13C HSCQ NMR spectra. The spectral region of Hα-Cα correlations of A1 
and A5 is reported in the absence of FGF8b (black) and at 0.5:1 (blue) and 1:1 (red) FGF8b:ARPCA ratios. D. Inhibition of HSPG/FGF8b/
FGFR1 ternary complex formation by ARPCA. Data are the mean ± SEM of three determinations. **P < 0.01; #P < 0.001.
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Figure 2: ArPcA inhibits the angiogenic activity of FGF8b. A. HUVECs were stimulated with 30 ng/ml FGF8b in the presence 
of 60 µM ARPCA or ARPVA and immunostained with anti-FGFR1 (green) or anti-pFGFR1 (red) antibodies. Scale bar: 30 µm. Intensity 
of pFGFR1/FGFR1 signal was quantified and normalized to DAPI area (DAPI is in blue). The boxes extend from the 25th to the 75th 
percentiles, the lines indicate the median values, and the whiskers indicate the range of values. NS= not stimulated. b. Viable cell counting 
of HUVECs treated for 48 h with ARPCA or ARPVA in the presence of 30 ng/ml FGF8b. c. HUVEC spheroids were embedded in fibrin 
gel and treated with 30 ng/ml FGF8b or VEGF-A in the absence or presence of 60 µM ARPCA or ARPVA. After 24 h of stimulation the 
number of HUVEC sprouts were counted. D. Alginate pellets containing 4.5 pmoles of FGF8b or VEGF-A in the absence or presence 
of the indicated doses of ARPCA or ARPVA were placed on the top of the chick embryo CAM at day 11 of incubation. At day 14 newly 
formed blood vessels converging towards the implants were counted (8 embryos/group). Representative images of CAMs treated with 
FGF8b in the absence or presence of 140 pmoles of ARPCA or ARPVA are shown on the right. Data are the mean ± SEM. **P < 0.01 vs 
NS; §P < 0.05 vs FGF8b and +ARPVA; *P < 0.05; #P < 0.001.
Figure 3: ArPcA inhibits the proliferation and angiogenic potential of FGF8b-dependent tumor cells. A. S115 cells 
were treated with ARPCA or ARPVA in the presence of 30 ng/ml FGF8b or 10 nM DHT. Viable cells were counted 48 h thereafter. b. 
Western blot analysis of S115 cells treated with 30 ng/ml FGF8b in the absence or presence of 100 µM ARPCA or ARPVA. c. Alginate 
beads containing 2.5 x 104 DHT-treated S115 cells were grafted onto the CAM at day 11 of incubation in the absence or presence of the 
indicated doses of ARPCA or ARPVA. At day 14, newly formed blood vessels were counted (8 embryos/group). Data are the mean ± SEM. 
#P < 0.001.
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ArPcA inhibits the proliferation and angiogenic 
potential of FGF8b-dependent tumor cells
Shionogi-115 (S115) cells represent a well-
characterized murine model of androgen-regulated 
mammary tumor in which testosterone induces FGF8b 
upregulation that, in turn, increases FGFR1 expression, 
thus activating an autocrine loop of stimulation [16, 21]. 
As shown in Figure 3A, ARPCA impairs the mitogenic 
response of S115 cells to FGF8b or dihydrotestosterone 
(DHT) whereas ARPVA was ineffective. Accordingly, 
ARPCA, but not ARPVA, inhibits FGFR1 phosphorylation 
and downstream mitogen-activated protein kinase 
(MAPK) ERK1/2 activation in S115 cells treated with 
FGF8b (Figure 3B).
FGF8b produced by steroid hormone-regulated 
cancers promotes angiogenesis that sustains tumor 
growth in vivo [21]. To assess the effect of ARPCA on 
the angiogenic potential of FGF8b-producing tumor 
cells, S115 cells were incubated for 24 h with 10 nM 
DHT and then grafted onto the chick embryo CAM. As 
shown in Figure 3C, DHT-pretreated cells elicited a potent 
neovascular response that was abolished when cells were 
grafted in the presence of ARPCA at 80 or 140 pmoles/
embryo (P < 0.001), no effect being exerted by control 
ARPVA. Together, these data indicate that ARPCA impairs 
the FGF8b-dependent mitogenic and angiogenic response 
triggered by DHT/FGF8b in S115 cells.
ArPcA inhibits the in vivo growth of steroid 
hormone-regulated tumors
In order to assess the effect of ARPCA on the early 
phases of growth of FGF8b-dependent tumor grafts, S115 
cells encapsulated in sodium alginate gel were injected 
s.c. in the flank of adult athymic Nu/Nu male mice. Then, 
mice were treated i.p. with 100 mg/kg of ARPCA or 
ARPVA on days 9, 11 and 13 after tumor challenge. On 
day 14 alginate plugs were harvested and processed for 
immunohistochemical analysis. 
As shown in Figure 4A, treatment with ARPCA 
efficiently inhibited FGFR1 phosphorylation, Ki67+ 
Figure 4: ArPcA inhibits the in vivo growth FGF8b/DHt-regulated s115 tumors. A. Athymic male mice were implanted s.c. 
with alginate plugs containing S115 cells and treated i.p. every other day with 100 mg/kg of ARPCA or ARPVA (6 mice/group). After one 
week of treatment, plugs were harvested and processed for FGFR1, pFGFR1, Ki67 and CD31 immunofluorescence analysis. Scale bars: 30 
µm (FGFR1 and pFGFR1) and 100 µm (H&E, Ki67, CD31). Intensity of pFGFR1/FGFR1 signal and Ki67+ or CD31+ areas were quantified 
and normalized to DAPI area (DAPI is in blue). b. Long-term tumor growth of S115 cells grafted s.c. in athymic male mice treated i.p. 
with vehicle or 100 mg/kg ARPCA or ARPVA. Treatments are indicated by arrows. At the end of the experiment, tumors were harvested, 
photographed and weighted (10-12 mice/group). Data are the mean ± SEM; *P < 0.05, **P < 0.01, #P < 0.001.
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proliferation index and CD31+ neovascularization in tumor 
grafts when compared to lesions harvested from ARPVA-
treated animals, thus confirming the inhibitory effect 
of ARPCA on in vivo S115 cell growth and angiogenic 
potential. On this basis, we performed a long-term 
experiment in which Nu/Nu male mice were injected s.c. 
with S115 cells and treated i.p. every other day with 100 
mg/kg of ARPCA starting at day 8, when tumors were 
palpable. Tumor growth was followed for the next 32 days 
when tumors were harvested and weighted. The results 
demonstrate that ARPCA, but not ARPVA, suppresses 
S115 tumor growth (Figure 4B). 
Previous observations had shown that FGF8b and 
FGF2 play a key role in prostate cancer and that PTX3 
overexpression inhibits the FGF8b/FGF2-driven growth 
of TRAMP-C2 tumors [15], an androgen-responsive 
murine model of prostate carcinoma [22]. Given the 
capacity of ARPCA to act as a FGF2/FGF8b-trap ( [20] 
and present work), we assessed its therapeutic potential 
also in this steroid-regulated tumor model driven by the 
autocrine/paracrine action of both FGFs. To this purpose, 
TRAMP-C2 cells were embedded in alginate plugs 
and injected s.c. in syngeneic C57BL/6 male mice. As 
observed for early S115 lesions, treatment with ARPCA 
(i.p. at 100 mg/kg every other day) impaired FGFR1 
activation in TRAMP-C2 alginate plugs, thus leading to 
a decrease of the tumor cell proliferation rate (as assessed 
by Ki67 immunostaining) and of CD31-positive tumor 
vascularization (Figure 5A). Accordingly, ARPCA, but 
not ARPVA, inhibited the growth of TRAMP-C2 tumor 
grafts in a long-term assay (Figure 5B). Of note, long-
term administration of ARPCA did not affect body weight, 
hematologic parameters, blood serum components and 
FGF23 serum levels in treated animals (Figure 6).
 DIscUssION
FGF8b affects epithelial/stromal compartments of 
steroid hormone-regulated tumors by exerting an autocrine 
activity on cancer cells and a paracrine pro-angiogenic 
function that may contribute to tumor progression [4-6, 
8]. Indeed, FGF8b is overexpressed in a high proportion 
of human breast [25] and aggressive prostate cancers [26]. 
Also, FGF8b plays a non-redundant role in the activation 
of FGFR signaling cascade that confers resistance to 
hormone deprivation therapy and drives the progression 
toward a hormone-independent neoplasm [27]. On this 
basis, the FGF/FGFR system has been hypothesized as 
a target for the treatment of steroid hormone-regulated 
tumors [4, 27, 28], also in a possible synergistic 
combination with radiotherapy or classical chemotherapy 
[29]. 
Previous observations had shown that the soluble 
pattern recognition receptor PTX3 binds FGF8b and 
inhibits the angiogenic and tumorigenic activity of 
androgen-regulated tumor cells in which testosterone 
activates a FGF8b-dependent autocrine/paracrine loop 
of stimulation [15]. PTX3 interacts with different ligands 
via its N-terminal or C-terminal domain [12, 17]. An 
integrated approach that utilized recombinant N-terminal 
and C-terminal PTX3 fragments, monoclonal antibodies, 
and SPR analysis identified the FGF2-binding domain 
in the PTX3 N-terminus [14]. Moreover, as observed 
for FGF2 [13, 14], a free recombinant N-terminal PTX3 
fragment prevented the binding of FGF8b to immobilized 
PTX3 [16], thus implicating the N-terminal PTX3 
extension also in this interaction. 
Here, we demonstrate that the pentapeptide ARPCA, 
corresponding to the amino acid sequence 100-104 in 
PTX3 N-terminus, represents a novel FGF8b antagonist 
endowed with antiangiogenic and antineoplastic activity. 
Indeed, ARPCA binds FGF8b, thus preventing the 
formation of signalling HSPG/FGF8b/FGFR1 ternary 
complexes. Accordingly, ARPCA inhibits the angiogenic 
activity exerted in vitro and in vivo by FGF8b. Also, 
ARPCA inhibits the proliferation and angiogenic potential 
of androgen-regulated murine mammary S115 tumor 
cells driven by FGF8b as well as by testosterone. As a 
result of its ability to inhibit both paracrine and autocrine 
functions of FGF8b, ARPCA exerts a significant inhibitory 
effect on FGFR1 phosphorylation, cell proliferation, 
angiogenic and tumorigenic activity of S115 tumor 
grafts in immunodeficient male mice. Furthermore, 
ARPCA inhibits the FGF8b/FGF2-driven growth and 
vascularization of TRAMP-C2 tumors, an androgen-
responsive murine model of prostate carcinoma [22].
Notably, the anti-tumor action of ARPCA occurred 
in the absence of any systemic toxic effect in treated 
animals. In particular, at variance with other inhibitors of 
the FGF/FGFR system [30], the safety profile of ARPCA 
treatment included the absence of any effect on the blood 
levels of FGF23, calcium and phosphorus. Accordingly, 
SPR analysis did not show any interaction of ARPCA with 
immobilized FGF23 (data not shown).
VEGF plays a central role in tumor 
neovascularization and inhibition of the VEGF/VEGF 
receptor system markedly disrupts angiogenic switching 
and initial tumor growth. However, targeting FGFs in 
addition to VEGF might show synergistic effects in the 
treatment of angiogenesis-dependent diseases, including 
cancer [1, 31]. Also, experimental evidences indicate that 
drug resistance to VEGF blockade may occur following 
reactivation of the angiogenic process triggered by the 
compensatory upregulation of the FGF/FGFR system in 
experimental tumor models [32] and in cancer patients 
[33], representing a mechanism of escape to anti-
VEGF therapy in cancer treatment [31]. Our preclinical 
observations support the notion that inhibition of FGF8b 
activity by ARPCA suppresses the initial phases of growth 
and vascularization of androgen-regulated tumors, thus 
resulting in the inhibition of tumor progression in long-
term tumor assays. This occurs despite the fact that 
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Figure 5: ArPcA inhibits the in vivo growth of FGF8b/FGF2/DHt-regulated trAMP-c2 tumors. A. C57BL/6 male 
mice were implanted s.c. with alginate plugs containing TRAMP-C2 cells and treated i.p. every other day with 100 mg/kg of ARPCA 
or ARPVA (6 mice/group). After one week of treatment, plugs were harvested and processed for FGFR1, pFGFR1, Ki67 and CD31 
immunofluorescence analysis. Scale bars: 30 µm (FGFR1 and pFGFR1) and 100 µm (H&E, Ki67, CD31). Intensity of pFGFR1/FGFR1 
signal and Ki67+ or CD31+ areas were quantified and normalized to DAPI area (DAPI is in blue). b. Long-term tumor growth of TRAMP-C2 
cells grafted s.c. in C57BL/6 male mice treated i.p. with vehicle or 100 mg/kg ARPCA or ARPVA. Treatments are indicated by arrows. At 
the end of the experiment, tumors were harvested, photographed and weighted (10-12 mice/group). Data are the mean ± SEM; ** < 0.01, 
#P < 0.001.
Figure 6: body weight variation and hematological parameters of mice after treatment with ArPcA. A. C57BL/6 mice 
were treated i.p. every other day for two weeks with ARPCA at 100 mg/kg (arrows). At different time points, the percentage of body 
weight variation was calculated in respect to Day 0. B) At the end of ARPCA treatment (Day 14), blood components, biochemical serum 
parameters and FGF23 serum levels were determined. Data are the mean ± standard deviation of 3 or more animals. 
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ARPCA does not affect the pro-angiogenic action of 
VEGF-A and may be related to its ability to affect both 
tumor epithelial and stromal compartments by suppressing 
the autocrine/paracrine action of FGF8b that is essential 
for the initial angiogenic and proliferative switch of tumor 
cells.
Various amino acid substitutions in the ARPCA 
sequence, including the removal of the N-terminal 
blocking acetyl group, cause a dramatic decrease in the 
FGF8b-binding capacity of the corresponding mutated 
synthetic pentapeptides, pointing to the relevance of each 
amino acid residue for ARPCA/FGF8b interaction. NMR 
experiments demonstrate that Ala1 and Ala5 make direct 
contacts with the FGF8b protein and the involvement of 
their methyl groups in FGF8b interaction is supported 
by the observed lack of activity of the Ac-GRPCG-NH2 
mutant. On the other hand, the RPC sequence plays a 
conformational role in ARPCA/FGF8b interaction and 
may help to orient the methyl groups of the peptide for 
optimal interaction with the growth factor. This hypothesis 
is supported by the lack of FGF8b-binding activity of Pro3 
or Cys4 peptide mutants and of the partially scrambled 
Ac-APCRA-NH2 peptide.
Hydrophobic interactions are implicated in 
ARPCA binding to FGF8b. X-ray crystallography data 
have shown that hydrophobic interactions dominate the 
interface between FGFs and the D2 domain of the FGFR 
extracellular moiety [34, 35]. On this basis, ARPCA 
likely exerts its FGF antagonist activity by mimicking the 
hydrophobic region of D2, thus competing with FGFRs 
for the binding to the growth factor, as hypothesized for 
ARPCA/FGF2 interaction [20]. Indeed, ARPCA hampers 
the capacity of FGF8b to form FGFR1-mediated ternary 
complexes with HSPGs, thus inhibiting FGFR1 activation 
and signalling triggered by FGF8b in endothelial and 
cancer cells. It must be pointed out that the unique 
spatial positioning of the FGF8b N-terminal g-helix 
allows for a hydrophobic contact also with the groove in 
the FGFR D3 domain [35], thus representing a possible 
alternative/additional ARPCA interaction site for FGF8b 
(Supplemental Figure S1). Further studies will be required 
to unambiguously define the molecular bases of ARPCA/
FGF8b interaction.
Previous findings had shown that ARPCA is 
endowed with a potent anti-FGF2 activity in vitro and 
in vivo [20]. Here, we demonstrate the ability of ARPCA 
to antagonize also the pro-angiogenic and tumorigenic 
activity of FGF8b. Accordingly, ARPCA exerts a 
significant inhibitory on the growth and vascularization 
of TRAMP-C2 tumor grafts, a classical model of steroid 
hormone-dependent prostate cancer characterized by 
FGF2/FGF8b co-expression. Thus, ARPCA may act as 
a FGF2/FGF8b antagonist able to affect tumor epithelial 
and stromal compartments by suppressing the autocrine/
paracrine action of both growth factors. Relevant to this 
point, SPR experiments indicate that ARPCA is able 
to interact also with other members of the FGF family, 
including FGF1, FGF5, FGF7, FGF16, FGF17, FGF18, 
FGF20 and FGF22 (Table 1). All these FGFs have been 
shown to play a role in different human cancers [36-42]. 
Experiments are in progress to translate the information 
about ARPCA/FGF interaction into a pharmacophore 
model to be used for the screening of small molecule 
databases [43], in the search for a novel low molecular 
weight multi-FGF trap for the therapy of FGF-driven 
cancers.
MAtErIALs AND MEtHODs
reagents and cell culture
Human recombinant FGF8b was from PeproTech, 
ARPCA, ARPVA and scrambled peptides were kindly 
provided by R. Longhi and A. Gori (CNR, Milano, Italy). 
Recombinant FGF8b for NMR studies was produced and 
purified by ASLA (Riga, Latvia. EU). Alginic acid sodium 
salt was from Sigma-Aldrich (Saint Louis, MO, USA).
table 1: surface plasmon resonance (sPr) analysis 
of FGF/ArPcA interaction. The capacity of increasing 
concentrations of ARPCA (ranging between 8 µM 
and 2000 µM) to bind canonical and hormonal FGFs 
immobilized to Biacore sensor chips was assessed by SPR 
analysis. Then, equilibrium (plateau) values of the SPR 
sensorgrams were used to build the binding isotherms that 
were fitted with the Langmuir equation for monovalent 
binding. This allowed to evaluate the mass surface 
dissociation constant, Kd. n.b. = no binding.
FGFs Kd (µM)(mean ± sEM)
                     FGF1 subfamily
FGF1 227 ± 46
FGF2 1700 ± 100




                     FGF7 subfamily
FGF3 n.b.
FGF7 885 ± 240
FGF10 n.b.
FGF22 129 ± 57
                     FGF8 subfamily
FGF8b 278 ± 120
FGF17 476 ± 265
FGF18 26 ± 4
                     FGF9 subfamily
FGF9 n.b.
FGF16 112 ± 23
FGF20 264 ± 97
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HUVECs were used at passages I–IV and grown 
on plastic surface coated with porcine gelatin (Sigma-
Aldrich) in M199 medium (Invitrogen, Carlsbad, CA, 
USA) supplemented with 20% fetal bovine serum (FBS) 
(Invitrogen), endothelial cell growth factor (100 µg/mL) 
(Sigma-Aldrich), and porcine heparin (100 µg/mL, Sigma-
Aldrich). S115 mouse mammary carcinoma cells were 
kindly provided by M. Jalkanen (Biotie, Turku, Finland) 
and maintained in DMEM supplemented with 5% heat-
inactivated FBS, 1 mM sodium pyruvate, 1 mM glutamine 
and 10 mM testosterone (DHT). Murine prostate 
adenocarcinoma TRAMP-C2 cells were obtained from 
ATCC repository and maintained in DMEM supplemented 
with 10% heat inactivated FBS, 10 mM HEPES buffer, 
0.5 mM 2-mercaptoethanol, 2.0 mM glutamine, 5 mg/ml 
bovine insulin (Sigma-Aldrich) and 10 nM DHT. Cells 
were maintained at low passage, returning to original 
frozen stocks every 3 to 4 months, and tested regularly for 
Mycoplasma negativity.
surface Plasmon resonance (sPr) analyses
A BIAcore X-100 apparatus (BIAcore Inc., 
Piscataway, NJ, USA) was used to set up the following 
experimental models. ARPCA and all the peptides 
mentioned in the present work were analyzed for their 
capacity to directly bind to immobilized FGF8b. To this 
purpose, FGF8b (20 µg/ml in 10 mM sodium acetate, pH 
6.0) was allowed to react with a flow cell of a CM5 sensor 
chip that was previously activated with a mixture of 0.2 
M N-ethyl-N’-(3-dimethylaminopropyl)-carbodiimide 
hydrochloride and 0.05 M N-hydroxysuccinimide (35 
µl, flow rate 10 µl/min). After ligand immobilization, 
matrix neutralization was performed with 1.0 M 
ethanolamine (pH 8.5) (35 µl, flow rate 10 µl/min) and 
the activated/deactivated dextran was used as reference 
(control) system. Increasing concentrations of ARPCA 
(ranging between 8 µM and 2000 µM) were injected 
over the FGF8b-coated sensor chip and the response was 
recorded as a function of time tracking the SPR intensity 
change upon binding progression. Injection lasted for 4 
min (flow rate 30 µl/min) to allow peptide association 
to immobilized FGF8b and was followed by 10 min of 
dissociation; each run was performed in HBS and the 
sensor chip was regenerated with 10 mM NaOH. The 
equilibrium (plateau) values of the SPR sensorgrams were 
used to build the binding isotherms (dose-response curves) 
displayed. Binding isotherm points were fitted with the 
Langmuir equation for monovalent binding. This allowed 
to evaluate the mass surface dissociation constant, Kd, and 
the scaling parameter that relates the SPR signal with the 
extent of binding, as the free parameters of the fitting. The 
errors on these parameters were assigned as a result of 
the fitting algorithm (95% confidence bounds). The best-
fitting procedure was performed with the SigmaPlot 11.0 
software package (Systat Software Inc.). Others FGFs 
were dissolved in 10mM sodium acetate at optimal pH, 
immobilized on CM5 sensorchips and tested for their 
capacity to bind ARPCA as described above. 
ArPcA-FGF8 interactions assessed by NMr
NMR experiments were collected on samples 
containing 190 μM of ARPCA, dissolved in 50 mM 
potassium phosphate buffer pH 6.7 (90% H2O/10% D2O), 
2.5 mM arginine, 10mM NaCl in the presence of variable 
concentrations of FGF8 corresponding to 1:0, 1:0.5, and 
1:1 ARPCA:FGF8 ratios.
2D 1H-13C HSQC spectra were recorded with a 
sweep width of 10 ppm and 100 ppm.2k x 128 data points 
were used in proton and carbon dimensions, respectively. 
Data, acquired and processed using Topspin (Bruker 
Biospin), were apodized with a squared sinebell shifted by 
90° and polynomial baseline correction. All NMR spectra 
were recorded at 298 K with a Bruker DMX spectrometer 
operating at 600 MHz.
HsPG/FGF8b/FGFr1 mediated cell-cell adhesion 
assay 
This assay was performed as described [44] with 
minor modifications. Briefly, wild-type CHO-K1 cells 
were seeded in 24-well plates at 150000 cells/cm2. After 24 
h, cell monolayers were washed with PBS and incubated 
with 3% glutaraldehyde in PBS for 2 h at 4°C. Fixation 
was stopped with 0.1 M glycine and cells were washed 
extensively with PBS. Then, A745-CHO-flg-1A-luc cells 
(50000 cells/cm2) were added to CHO-K1 monolayers in 
serum-free medium plus 10 mM EDTA with or without 
30 ng/ml FGF8b in the absence or presence of increasing 
concentrations of the ARPCA or ARPVA peptides. After 
2 h of incubation at 37°C, unattached cells were removed 
by washing twice with PBS, and A745-CHO-flg-1A-luc 
bound to the CHO-K1 monolayer were solubilized and 
luciferase activity was quantified. All experiments were 
performed in triplicate.
cell proliferation assays
HUVECs were seeded at 18000 cells/cm2 in 
medium containing 2.5% FBS and stimulated with 30 
ng/ml FGF8b in the absence or presence of increasing 
concentrations of ARPCA or ARPVA. S115 cells were 
seeded at 15000 cells/cm2 in medium containing 4% 
hormone-deprived dextran-coated charcoal-stripped heat 
inactivated FBS, followed by 24 h serum starvation in 
1:1 mixture of serum-free Ham’s F12 and DMEM. Cells 
were stimulated for 48 h with 30 ng/ml FGF8b or 10 nM 
DHT in the presence or absence of different concentrations 
of ARPCA or ARPVA (as specified in the corresponding 
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figures). Viable cell counts were obtained by the counting 
function of the MACSQuant Analyzer (Miltenyi Biotec, 
Bergisch-Gladbach, Germany, EU).
Endothelial cell sprouting assay
HUVEC spheroid aggregates were prepared in 20% 
methylcellulose medium, embedded in fibrin gel, and 
stimulated with FGF8b or VEGF-A (both at 30 ng/ml) plus 
5% FBS in the absence or presence of 60 µM ARPCA 
or ARPVA. Formation of radially growing cell sprouts 
was observed during the next 24 h, photographed at 200x 
magnification using an Axiovert 200M microscope (Carl 
Zeiss, Milan, Italy, EU) and counted.
Western blotting
S115 cells were treated with FGF8b (30ng/ml) in the 
presence or absence of ARPCA (100 µM) or ARPVA (100 
µM). After 20 minutes of incubation cell samples were 
washed in cold PBS and homogenized in RIPA buffer 
containing 1% Triton-X100, 0.2% BriJ, 1 mM sodium 
orthovanadate and protease inhibitors cocktail. Protein 
concentrations were determined using the Bradford protein 
assay (Bio-Rad Laboratories, Milano, Italy). Blotting 
analysis was performed using anti-FGFR1, anti-phospho 
FGFR1 and anti-phosphoERK1/2 antibodies (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). Equal loading of 
the lanes was confirmed by immunoblotting with anti–
αTubulin (Sigma-Aldrich) antibody.
In vitro immunofluorescence analysis 
HUVECs were seeded in Ibidi µ-Slide 8 wells 
(Ibidi, Martinsried, Germany, EU) at a density of 30000 
cells/cm2, starved in 2.5% FBS for 24 h and stimulated 
for 20 minutes with 30 ng/ml of FGF8b in the absence 
or presence of ARPCA or ARPVA. Following stimulation, 
cells were washed twice in PBS, fixed in cold acetone 
for 5 minutes and permeabilized with 0.2% Triton-X100 
in PBS for 2 minutes at room temperature (RT). After 
washing in PBS, cells were blocked for 10 minutes at RT 
in 1% BSA and then incubated with rabbit anti-pFGFR1 or 
rabbit anti-FGFR1 antibodies (Santa Cruz Biotechnology) 
for 1 h at RT. After washing in PBS, cells were incubated 
with AlexaFluor 594-conjugated anti-rabbit antibody 
(Invitrogen) and DAPI for 30 minutes at RT. Finally, cells 
were examined under a Zeiss Fluorescence Axiovert 200M 
microscope (Carl Zeiss).
chick embryo chorioallantoic membrane (cAM) 
assay
Alginate plugs containing vehicle, FGF8b (4.5 
pmoles/embryo), VEGF-A (4.5 pmoles/embryo) or 
S115 cells (2.5x104/embryo) in the absence or presence 
of ARPCA (80 or 140 pmoles/embryo) or ARPVA (140 
pmoles/embryo) were placed on the CAM of fertilized 
white leghorn chicken eggs at day 11 of incubation. At day 
14, newly formed blood microvessels converging toward 
the implant were counted by two observers in a double-
blind fashion at 5x magnification under a stereomicroscope 
(STEMI-SR, x2/0.12; Zeiss) as described [24]. 
Murine s.c. alginate implant assay
Eightweek-old athymic Nu/Nu or C57BL/6 male 
mice were injected s.c. with 450 μl of 3% (w/v) sodium 
alginate solution (alginic acid dissolved in LPS-free 
PBS) containing 5x106 S115 or 8x106 TRAMP-C2 
cells, respectively [15]. Mice were treated i.p. with 
ARPCA or ARPVA (100 mg/kg) on day 7, 9, 11 and 13 
after implant. On day 14, alginate gels were harvested, 
weighted, embedded in OCT-compound and immediately 
frozen to be processed for histological analysis. For 
immunofluorescence stainings, sections (5 μm thick) 
were obtained with a cryostat microtome, air dried and 
fixed with acetone (for 5 min at 4°C). After blocking 
with 1% BSA (Bovine Serum Albumin) in PBS for 10 
minutes, sections were incubated with primary antibodies, 
rabbit anti-FGFR1 (Santa Cruz Biotechnology), rabbit 
anti-phospho FGFR1 (Santa Cruz Biotechnology), Ki67 
(Dako, Milano, Italy, EU) or CD31 (BD Biosciences 
Pharmingen, San Diego, CA, USA). After washing with 
PBS containing 0.05% Tween 20, sections were incubated 
with the appropriate Alexa Fluor 488 or Alexa Fluor 
594-conjugated secondary antibody (Invitrogen). After 
mounting in a drop of anti-bleaching mounting medium 
containing DAPI (Vectashield, Vector Laboratories, 
Burlingame, CA, USA), sections were examined under 
a Zeiss Fluorescence Axiovert 200M microscope (Carl 
Zeiss).
In vivo tumor therapy studies
Eight week old C57BL/6 male mice were injected 
s.c. with 8x106 TRAMP-C2 cells, and eight week old 
athymic Nu/Nu male mice were injected s.c. with 5x106 
S115 cells. All injections were performed in 200 µl total 
volume of PBS into the dorsolateral flank. When tumors 
were palpable treatment was performed every other day 
by i.p. injection of ARPCA, ARPVA (both at 100 mg/
kg) or vehicle (PBS) in 100 µl final volume. Tumors 
were measured in two dimensions and tumor volume 
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was calculated according to the formula V=(D x d2)/2, 
where D and d are the major and minor perpendicular 
tumor diameters, respectively [45]. At the end of the 
experimental procedure tumors were harvested, weighted 
and photographed.
In vivo ArPcA toxicity studies 
Eight week-old C57BL/6 mice were treated i.p. 
with 100 mg/kg of ARPCA every other day for two 
weeks. During this period, animals were weighted for 
body weight variation analysis. At the end of treatment, 
whole blood and serum were harvested and analysed for 
blood components, biochemical serum parameters and 
circulating levels of FGF23. The serum levels of FGF23 
were assessed by ELISA (Uscn Life Science Inc., Wuhan, 
PRC, Asia) according to manufacturer’s instructions. 
Untreated mice were used as reference/control.
statistical analysis
Statistical analyses were performed using the 
statistical package Prism 5 (GraphPad Software). 
Student’s t test for unpaired data (2-tailed) was used to 
test the probability of significant differences between 
two groups of samples. For more than two groups of 
samples, data were statistically analyzed with a 1-way 
analysis of variance, and individual group comparisons 
were evaluated by the Bonferroni multiple comparison 
test. Tumor volume data were statistically analyzed 
with a 2-way analysis of variance, and individual group 
comparisons were evaluated by the Bonferroni correction. 
Differences were considered significant when P < 0.05.
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